Next-generation sequencing may help identify patients with smoldering multiple myeloma at high risk for disease progression.

News

Patients with relapsed or refractory multiple myeloma should be given individualized treatment based on numerous factors, including biology of the disease and type of relapse, according to a presentation at the 12th Annual National Comprehensive Cancer Network (NCCN) Congress: Hematologic Malignancies (October 6-7, 2017; San Francisco, CA).

Read More

Results of eight recent clinical trials show that older patients treated for relapsed or refractory multiple myeloma with novel therapies had similar rates of progression-free survival (PFS) as younger patients.

The analysis was presented at the 2017 European Society for Medical Oncology Congress (September 8-12, 2017; Madrid, Spain).

Read More

Daratumumab-based combination therapies (DCTs) are ineffective in patients with multiple myeloma who have been heavily pre-treated or are refractory to one or more agents in a DCT, according to a recent study published in American Journal of Hematology (online August 11, 2017; doi:10.1002/ajh.24883).

Read More

By Will Boggs MD

NEW YORK (Reuters Health) - Lenalidomide maintenance therapy after autologous stem-cell transplantation (ASCT) prolongs the time to remission in patients with multiple myeloma (MM), according to an updated analysis of the CALGB 100104 phase 3 trial.

Read More

Research in Review

A triple-combination treatment strategy is the most effective therapy for patients with relapsed or refractory multiple myeloma, according to a meta-analysis published in the Journal of Clinical Oncology (published online February 27, 2017; doi:10.1200/JCO.2016.71.1663).

-----

Related Content

Read More

The addition of bortezomib to lenalidomide with dexamethasone treatment significantly improves progression-free survival (PFS) and overall survival (OS) for patients with multiple myeloma, according to new clinical trial results.

-----

Related Content

Read More

 

There is significant variation in how European practices treat patients with multiple myeloma, according to a cross-sectional study published in the British Journal of Haematology.

Read More

Daratumumab may be the most cost-effective treatment option for patients with multiple myeloma (MM) compared with other novel therapies, according to a poster presented at the 2016 American Society of Clinical Oncology Annual Meeting (June 3-7; Chicago, IL).

Read More

Subscribe to Hematologic Malignancies